Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
A legfontosabb adatok
- Ki végzi
- Hellenic Institute for the Study of Sepsis
- Hol
- Görögország29 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 330 fő, tervezett
- Kezdés
- 2024. febr. 15.
- Várható befejezés
- 2027. febr. 28.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Clarithromycin 500mg
- Tablets
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (29)A regiszter feltételeinek elrejtése
Ki vehet részt
- Age equal to or above 18 years
- Male or female gender
- In case of women of reproductive age, willingness to use dual contraceptive method during the study period
- Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
- Community-acquired pneumonia (CAP)
- Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain
- PCT ≥0.25 ng/ml
- suPAR ≥6 ng/ml
Ki nem vehet részt
- Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days
- Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation
- Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation
- Concomitant presence of end-stage liver failure and end-stage renal failure
- Any stage IV malignancy
- Infection by SARS-CoV-2
- Known infection by the human immunodeficiency virus
- Medical history of allergy to macrolides
- Medical history of torsades de pointes arrhythmia
- QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome
- Age below 18 years
- Denial of written informed consent
- Any do not resuscitate decision
- Patients necessitating non-invasive ventilation or mechanical ventilation
- Hospitalization in Intensive Care Unit
- Intake of any macrolide for the current episode of CAP under study
- Any chronic anti-cytokine treatment for more than two months
- Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored
- Any contradictions for macrolide uptake
- Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
- Participation in any other interventional trial within the last 30 days
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.
A vizsgálat 2 csoportja
- PlaceboPlacebo, összehasonlításként
These patients will be treated with 1 placebo tablet every 12 hours and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
Kezelés: Tablets
- ClarithromycinMár használt kezelés, összehasonlításként
These patients will be treated with oral clarithromycin 500 mg twice daily for seven days and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
Kezelés: Clarithromycin 500mg
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial
- A regiszteradat frissítve
- 2026. november 18.